Cargando…
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
The clinical success of anti-CD20 monoclonal antibody (mAb)-mediated B cell depletion therapy has contributed to the understanding of B cells as major players in several autoimmune diseases. The first therapeutic anti-CD20 mAb, rituximab, is a murine–human chimera to which many patients develop anti...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688039/ https://www.ncbi.nlm.nih.gov/pubmed/29143151 http://dx.doi.org/10.1007/s13317-017-0100-y |